AR069195A1 - Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa - Google Patents

Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa

Info

Publication number
AR069195A1
AR069195A1 ARP080104837A ARP080104837A AR069195A1 AR 069195 A1 AR069195 A1 AR 069195A1 AR P080104837 A ARP080104837 A AR P080104837A AR P080104837 A ARP080104837 A AR P080104837A AR 069195 A1 AR069195 A1 AR 069195A1
Authority
AR
Argentina
Prior art keywords
lactose
pharmaceutically acceptable
combination
oract
strogen
Prior art date
Application number
ARP080104837A
Other languages
English (en)
Inventor
Beate Burglen
Manuela Pfeifer
Sabine Fricke
Claus Claussen
Ralf Ladwig
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR069195A1 publication Critical patent/AR069195A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Los gestágenos, con preferencia dienogest, acetato de clormadinona o levornogetrel en combinacion con estrogenos tales como, por ejemplo, etinilestradiol, 17beta-estradiol o valerato de estradiol y uno o varios excipientes/portadores farmacéuticamente aceptables realizan una anticoncepcion oral sin lactosa. Se da una posibilidad para mejorar la prevencion de la intolerancia a la glucosa en un factor que eventualmente contribuye con la mejoría, incluso en cuanto a costosos ensayos de la intolerancia a la glucosa. La solicitud también es apropiada para un uso prolongado.
ARP080104837A 2007-11-05 2008-11-05 Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa AR069195A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07021465A EP2055306A1 (de) 2007-11-05 2007-11-05 Verwendung eines Gestagens in Kombination mit einem Estrogen und einem oder mehreren pharmazeutisch annehmbaren hilfsstoffen/Trägern zur laktosefreien oralen Kontrazeption

Publications (1)

Publication Number Publication Date
AR069195A1 true AR069195A1 (es) 2010-01-06

Family

ID=39016019

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104837A AR069195A1 (es) 2007-11-05 2008-11-05 Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa

Country Status (31)

Country Link
EP (3) EP2055306A1 (es)
JP (1) JP2011502136A (es)
KR (1) KR20100103794A (es)
CN (1) CN101848716B (es)
AR (1) AR069195A1 (es)
AT (1) AT12800U1 (es)
AU (1) AU2008324549A1 (es)
BR (1) BRPI0819189A2 (es)
CA (1) CA2704523A1 (es)
CO (1) CO6270329A2 (es)
CR (1) CR11413A (es)
DE (1) DE202007019049U1 (es)
DK (1) DK2217243T3 (es)
DO (1) DOP2010000130A (es)
EA (1) EA201000749A1 (es)
EC (1) ECSP10010152A (es)
ES (1) ES2511841T3 (es)
HK (1) HK1145289A1 (es)
HR (1) HRP20140962T1 (es)
IL (1) IL205349A0 (es)
MX (1) MX2010004975A (es)
NZ (1) NZ585065A (es)
PA (1) PA8803001A1 (es)
PE (1) PE20091020A1 (es)
PL (1) PL2217243T3 (es)
PT (1) PT2217243E (es)
SG (1) SG188118A1 (es)
TW (1) TW200936142A (es)
UY (1) UY31454A1 (es)
WO (1) WO2009059690A1 (es)
ZA (1) ZA201004024B (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368373A1 (en) * 1988-10-13 1990-05-16 Akzo Nobel N.V. Multi-phase contraceptive preparation
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
JPH1171268A (ja) * 1997-08-28 1999-03-16 Kayaku:Kk 性ホルモン含有錠剤
CA2260673A1 (en) 1999-02-04 2000-08-04 Natrel Inc. A process for making a lactose-free milk without negatively affecting the organoleptic properties thereof; and milk so processed
DE10043846A1 (de) * 2000-09-04 2002-04-04 Jenapharm Gmbh 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
FR2832065B1 (fr) * 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
WO2005030176A1 (en) 2003-09-29 2005-04-07 Novo Nordisk Femcare Ag Improved stability of progestogen formulations
AU2004275469B2 (en) 2003-09-29 2010-07-15 Novo Nordisk Health Care Ag HRT formulations
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
DE102004019406A1 (de) * 2004-04-19 2005-11-03 Schering Ag 17α-Fluorsteroide
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
EP1690543A1 (de) * 2005-02-15 2006-08-16 Schering AG Pharmazeutisches Präparat zur Kontrazeption
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest

Also Published As

Publication number Publication date
IL205349A0 (en) 2010-12-30
DOP2010000130A (es) 2010-07-31
AU2008324549A1 (en) 2009-05-14
NZ585065A (en) 2012-06-29
EP2055306A1 (de) 2009-05-06
EP2217243B1 (de) 2014-08-06
JP2011502136A (ja) 2011-01-20
TW200936142A (en) 2009-09-01
HRP20140962T1 (hr) 2014-12-05
ECSP10010152A (es) 2010-06-29
WO2009059690A1 (de) 2009-05-14
BRPI0819189A2 (pt) 2015-05-26
DK2217243T3 (da) 2014-10-20
CA2704523A1 (en) 2009-05-14
CN101848716B (zh) 2012-11-28
ES2511841T3 (es) 2014-10-23
CO6270329A2 (es) 2011-04-20
EA201000749A1 (ru) 2010-12-30
CN101848716A (zh) 2010-09-29
DE202007019049U8 (de) 2010-09-30
EP2217243A1 (de) 2010-08-18
MX2010004975A (es) 2010-05-24
SG188118A1 (en) 2013-03-28
PL2217243T3 (pl) 2014-12-31
EP2774614A1 (de) 2014-09-10
PE20091020A1 (es) 2009-08-15
PA8803001A1 (es) 2009-06-23
CR11413A (es) 2010-06-17
UY31454A1 (es) 2009-05-29
HK1145289A1 (en) 2011-04-15
AT12800U1 (de) 2012-11-15
KR20100103794A (ko) 2010-09-28
PT2217243E (pt) 2014-09-24
DE202007019049U1 (de) 2010-05-12
ZA201004024B (en) 2012-11-28

Similar Documents

Publication Publication Date Title
RS50972B (sr) Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate
Schindler The “newer” progestogens and postmenopausal hormone therapy (HRT)
BRPI0512993A (pt) uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto
PE20070208A1 (es) Anticoncepcion oral con trimegestona
JP2010508275A5 (es)
ATE493132T1 (de) Arzneimittel umfassend wenigstens ein gestagen
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
ME00292B (me) Drospirenon za terapiju zamjene hormona
AR082998A1 (es) Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
JP2008515909A5 (es)
DK1443966T3 (da) Fremgangsmåde til forebyggelse eller behandling af benigne gynækologiske lidelser
AR049196A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
CO5580789A2 (es) Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis
AR069195A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa
CU20100084A7 (es) Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
ATE395047T1 (de) Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält
DOP2006000037A (es) Forma farmacológica peroral sólida para la anticoncepción
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
AR070302A1 (es) Composicion farmaceutica de un sistema de liberacion vaginal de esteroides
SI1937274T1 (sl) Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo
PE20020709A1 (es) Composiciones de complejos de estrogeno-ciclodextrina
TH124135A (es)
PE20091695A1 (es) COMBINACION FARMACEUTICA DE DROSPIRENONA Y 17ß-ESTRADIOL

Legal Events

Date Code Title Description
FB Suspension of granting procedure